- Home
- NDRA vs CDT Comparison
NDRA vs CDT Comparison
Compare NDRA & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDRA
- CDT
- Stock Information
- Founded
- NDRA 2007
- CDT 2019
- Country
- NDRA United States
- CDT United States
- Employees
- NDRA N/A
- CDT N/A
- Industry
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- NDRA Health Care
- CDT Health Care
- Exchange
- NDRA Nasdaq
- CDT Nasdaq
- Market Cap
- NDRA 2.3M
- CDT 2.2M
- IPO Year
- NDRA 2017
- CDT N/A
- Fundamental
- Price
- NDRA $3.58
- CDT $2.51
- Analyst Decision
- NDRA Strong Buy
- CDT
- Analyst Count
- NDRA 1
- CDT 0
- Target Price
- NDRA $46.00
- CDT N/A
- AVG Volume (30 Days)
- NDRA 32.0K
- CDT 725.7K
- Earning Date
- NDRA 08-13-2025
- CDT 08-11-2025
- Dividend Yield
- NDRA N/A
- CDT N/A
- EPS Growth
- NDRA N/A
- CDT N/A
- EPS
- NDRA N/A
- CDT N/A
- Revenue
- NDRA N/A
- CDT N/A
- Revenue This Year
- NDRA N/A
- CDT N/A
- Revenue Next Year
- NDRA N/A
- CDT N/A
- P/E Ratio
- NDRA N/A
- CDT N/A
- Revenue Growth
- NDRA N/A
- CDT N/A
- 52 Week Low
- NDRA $2.90
- CDT $2.21
- 52 Week High
- NDRA $197.75
- CDT $1,844.85
- Technical
- Relative Strength Index (RSI)
- NDRA 51.99
- CDT 31.11
- Support Level
- NDRA $3.14
- CDT $2.21
- Resistance Level
- NDRA $3.60
- CDT $2.58
- Average True Range (ATR)
- NDRA 0.20
- CDT 0.19
- MACD
- NDRA 0.05
- CDT 0.23
- Stochastic Oscillator
- NDRA 72.13
- CDT 54.45
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.